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Background. Treatment of human immunodeficiency virus (HIV)–infected women to prevent cervical cancer may stimulate 
HIV RNA cervical shedding and risk HIV transmission.
Methods. From 2011 to 2014, 400 HIV-infected women diagnosed with cervical intraepithelial neoplasia 2/3 in Kenya were ran-
domized to loop electrosurgical excision procedure (LEEP) or cryotherapy. Cervical samples were collected at baseline and 3 weekly 
intervals. Samples were tested for HIV RNA using the Gen-Probe Aptima HIV assay with a minimum detection level of 60 copies/
swab and analyzed using generalized estimating equations.
Results. Women who received LEEP had significantly higher cervical HIV RNA levels than those who received cryotherapy at 
weeks 2 (adjusted incident rate ratio [aIRR], 1.07; P = .038) and 3 (aIRR, 1.08; P = .046). Within LEEP, significantly higher cervical 
shedding was found at weeks 2 (2.03 log10 copies/swab; P < .001) and 3 (2.04 log10 copies/swab; P < .001) compared to baseline (1.80 
log10 copies/swab). Cervical HIV RNA was significantly higher following LEEP for up to 3 weeks among women on antiretroviral 
treatment (ART) (0.18 log10 copies/swab increase; P = .003) and in ART-naive women (1.13 log10 copies/swab increase; P < .001) 
compared to baseline. Within cryotherapy, cervical shedding increased in ART-naive women (0.72 log10 copies/swab increase; P = 
0.004) but did not increase in women on ART.
Conclusions. Women randomized to LEEP had a larger increase in post-procedural cervical HIV shedding than cryotherapy. 
Benefits of cervical cancer prevention outweigh the risk of HIV sexual transmission; our findings underscore the importance of 
risk-reduction counseling.
Clinical Trials Registration. NCT01298596.
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 Women infected with human immunodeficiency virus (HIV) 
experience a higher burden of cervical cancer than HIV-
uninfected women [1, 2]. Cervical cancer prevention depends 
on early diagnosis, treatment, and continued clinical follow-up. 
Globally, standard treatment modalities for cervical intraep-
ithelial neoplasia (CIN) include loop electrosurgical excision 
procedure (LEEP) and cryotherapy. LEEP is the standard of 
care for treatment of CIN in the United States and Europe [3, 4], 
and cryotherapy is commonly used in resource-limited settings 
that use a single-visit “see-and-treat” approach [5–10].
Treatment of CIN can cause inflammation or ulceration of 
the cervix [11, 12]. Increased risk of hemorrhage associated 
with LEEP and watery discharge with cryotherapy have been 
reported [13]. In HIV-infected women, these interventions may 
stimulate cervical shedding of HIV and subsequently increase 
the risk of HIV sexual transmission from treated women to 
HIV-uninfected partners [14]. While the risk of sexual HIV 
transmission from women on antiretroviral therapy (ART) 
is low, cervical HIV levels can differ from plasma HIV levels 
[15–20]. Both LEEP and cryotherapy have been associated with 
cervical shedding of HIV [11, 21–23]. However, they have never 
been directly compared to each other, and few studies have rig-
orously examined cervical shedding after these procedures in 
association with ART use, plasma viral load, and immunode-
ficiency [24].
We conducted a randomized, controlled trial (RCT) to com-
pare recurrence of cervical disease among women with high-grade 
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precancerous cervical lesions randomized to LEEP or cryotherapy 
[25]. Within the parent trial, we nested a substudy to compare the 
cervical HIV RNA levels at 1, 2, and 3 weeks following LEEP or 
cryotherapy and hypothesized that LEEP would be more likely to 
increase cervical HIV RNA levels compared to cryotherapy.
METHODS
Study Population
This study was nested within an RCT to compare recurrence 
of cervical lesions between LEEP and cryotherapy over 2-year 
follow-up. The RCT was performed at the Coptic Hope Center 
for Infectious Diseases, an urban HIV clinic in Nairobi, Kenya, 
that offers free, comprehensive HIV care and treatment with 
support from the President’s Emergency Plan for AIDS Relief 
[26]. Eligible HIV-infected women enrolled at the Coptic Hope 
Center who agreed to participate in the study were consented 
and screened for cervical cancer using Papanicolau (Pap) smear 
and colposcopy-directed biopsy. Women were eligible for the 
study if they were HIV infected, aged ≥18 years, had initiated 
sexual activity, were not pregnant, and had an intact cervix 
without history of hysterectomy. Women were excluded if they 
had a history of treatment for cervical lesions or if they had a 
lesion that was larger than 75% of the cervix surface or extended 
more than 2  mm into the endocervical canal. Women with a 
high grade squamous intraepithelial lesion or squamous cell 
carcinoma by Pap smear and histologically confirmed CIN2/3 
disease were randomized.
Randomization and Follow-up
Randomization was prepared using a computer-generated se-
quence in permuted blocks of 10, and assignment was in a 1:1 
allocation to receive LEEP or cryotherapy. Study investigators 
and participants were not blinded to the interventions. During 
the baseline visit, women completed a standardized question-
naire that detailed medical, sexual, and reproductive histories. 
ART use and duration were abstracted from the patient health 
record at the Coptic Hope Center.
Prior to treatment, endocervical swabs for HIV RNA were 
obtained by placing a sterile Dacron swab (Puritan, Guilford, 
Maine) on the outer part of the endocervix and rotating 
360 degrees in the cervical os. One swab was kept dry and an-
other swab was expressed into a cryotube that contained 1 mL 
of freezing media (70% Roswell Park Memorial Institute 1640 
medium, 20% fetal bovine serum, and 10% dimethyl sulfoxide; 
Sigma Life Science, St. Louis, Missouri). A blood sample was also 
collected for CD4 lymphocyte counts and plasma HIV RNA.
The cervix was colposcopically visualized, and Lugol’s solu-
tion was applied to outline the lesion and transformation 
zone. Prior to LEEP, the cervix was injected with 3–5 mL of 
anesthetic and Lugol’s solution. A  high-frequency electro-
surgical generator, Finesse II (Utah Medical Products Inc., 
Midvale, Utah) was inserted at a depth of 4–5 mm and drawn 
laterally across the cervix, and an additional pass with the loop 
was made only for large lesions to ensure complete excision. 
The study doctor performed cryotherapy using nitrous oxide 
with a 3-minute freeze, 5-minute thaw, and 3-minute freeze 
method.
The duration of treatment allowed for ice crystal formation 
that extended 4–5  mm beyond the tip of the cryotherapy to 
ensure tissue destruction of up to 5 mm in depth. Appropriate 
25 mm or 19 mm probes with either a flat surface or a shallow 
nipple were used according to the size and location of the lesion. 
Hemostasis was achieved following LEEP with electrocoagula-
tion or application of Monsel’s paste, or both. Following cryo-
therapy, Monsel’s paste was applied if bleeding was observed. 
Women were advised to abstain from sexual activity for 4 weeks 
following treatment. The same study doctor performed all clin-
ical procedures.
Women were scheduled for follow-up in the study clinic at 
7, 14, and 21 days after treatment. At each time point, cervical 
and plasma samples were collected, a physical examination was 
performed, and a standardized questionnaire was administered 
on acceptability of treatment and sexual activity.
Laboratory Testing
Cervical and plasma samples were stored at 80°C and shipped 
to the Fred Hutchinson Cancer Research Center in Seattle, 
Washington, on dry ice. HIV-1 RNA was quantified in cervical 
and plasma specimens using Gen-Probe APTIMA HIV assay 
(Hologic Gen-Probe Inc., San Diego, California). Specimens 
with <300  µL of cervical fluid were not sufficient for testing. 
The lower limit of HIV RNA detection was 60 copies/swab for 
cervical samples and 60 copies/mL for plasma samples. Samples 
that measured below the lower limit of detection were assigned 
the median value, 30 (1.48 log10) copies, between zero and the 
lower limit of detection. CD4 lymphocyte counts were deter-
mined using flow cytometry (Becton Dickinson Biosciences, 
San Jose, California).
Statistical Analyses
The targeted sample size of the parent RCT, 400 women (200 
per arm), was designed to detect a 10% difference in recurrence 
of CIN between treatment arms. This sample size was sufficient 
to detect a 0.25 log10 difference in cervical HIV RNA levels with 
>90% power. Cervical HIV shedding was compared between 
arms using intent-to-treat analysis.
Statistical analyses were performed using Stata version 14.1 
(Stata Corp., College Station, Texas). Generalized estimat-
ing equations with robust standard errors were used to model 
the mean change in cervical HIV RNA levels over time. We 
assumed an exchangeable correlation structure to account for 
intrasubject correlation and used a log link to interpret relative 
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Cervical HIV RNA was modeled as a log-transformed, con-
tinuous outcome. Weekly follow-up study visits were categorical 
variables defined as any study visit ±3 days of 7-, 14-, or 21-day 
time points post-treatment. The multivariate model included 
baseline cervical HIV RNA, an interaction term for treatment 
and time, detectable plasma HIV RNA, and dichotomous ART 
(on/off). We conducted subanalyses to evaluate change in cer-
vical HIV RNA levels by treatment arm. Each treatment arm 
was also stratified by women on or off ART because it was 
expected HIV RNA levels would vary by ART exposure.
The ethical review committees of the University of Washington 
and Kenyatta National Hospital approved the protocol.
RESULTS
Baseline Characteristics
Demographic and behavioral characteristics were balanced be-
tween the treatment arms (Table 1). Fewer women treated with 
cryotherapy had baseline CIN3, 54.5% (n = 109) compared to 
64.0% (n = 128) among women treated with LEEP. Baseline me-
dian CD4 count was 380 (interquartile range, 215–525) cells 
per mm3 in the overall cohort and did not differ significantly 
between the arms. Seventeen women (8.5%) in LEEP and 28 
(14%) in cryotherapy were off ART at the time of intervention. 
Most women (79.8%) reported exposure to ART for longer than 
6 months. At baseline, plasma viral load was similar between 
LEEP and cryotherapy (mean log10 HIV RNA, 2.17 vs 2.33; 
P = .224), and cervical shedding was significantly lower in LEEP 
(mean log10 HIV RNA, 1.80 vs 2.02; P = .009).
Cervical HIV RNA Following LEEP vs Cryotherapy
Among 400 women randomized to LEEP or cryotherapy in the 
parent RCT, 2 women (1.0%) in the LEEP and 3 (1.5%) in the 
cryotherapy arm had inadequate specimens at baseline. Of 600 
possible scheduled follow-up visits in the LEEP arm, 18 (3.0%) 
visits were missed, 51 (8.5%) were outside the ±3-day window, 
and 9 specimens were inadequate (1.5%). In the cryotherapy 
Table 1. Baseline Demographic, Behavioral, and Clinical Characteristics by Treatment Arm
Characteristic
Cryotherapy Loop Electrosurgical Excision Procedure
n Median (IQR) or % n Median (IQR) or %
Age (years) 200 38.2 (32.0–42.5) 200 37.4 (31.7–44.9)
Education (years) 200 11.0 (8.0–12.0) 200 11.0 (8.0–12.0)
Marital status 200 200
 Single 58 29.0 52 26.0
 Committed relationship 79 39.5 84 42.0
 Divorced/Separated/Widowed 63 31.5 64 32.0
Salaried employment 53 26.5 63 31.5
Monthly income 186 193
 <$50 44 23.7 48 24.9
 $50–$150 65 35.0 69 35.8
 >$150 77 41.4 76 39.4
Lifetime sexual partners 197 198
 1–2 88 44.6 67 33.8
 ≥3 93 47.2 113 57.0
Any hormonal contraception 36 18.1 32 16.0
Menses in last 7 days 39 20.1 33 16.8
Cervical intraepithelial neoplasia 3 109 54.5 128 64.0
CD4 (cells/mm3) 200 371 (213–532) 199 385 (221–522)
 <250 59 29.5 59 29.7
 250–499 83 41.5 84 42.2
 ≥500 58 29.0 56 28.1
No ART exposure 28 14.0 17 8.5
 ART exposure <30 days 3 1.5 6 3.0
 ART exposure 30 days–6 months 12 6.0 15 7.5
 ART exposure >6 months 157 78.5 162 81.0
Median ART exposure (months)a 172 29.4 (14.1–60.2) 183 34.0 (12.4–74.3)
Plasma HIV RNA ≥1.48 log10 copies/mL
c 72 37.0 67 34.7
Cervical HIV RNA ≥1.48 log10 copies/swab
b 61 31.0 42 21.2
Abbreviations: ART, antiretroviral therapy; HIV, human immunodeficiency virus; IQR, interquartile range. 
aAmong those on ART prior to treatment.
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arm, 17 (2.8%) visits were missed, 51 (8.5%) visits were out-
side the ±3-day window, and 9 (1.5%) had inadequate speci-
mens of <300 µL of cervical fluid (Figure 1). Fewer women in 
the LEEP arm engaged in sexual intercourse in the 3 weeks fol-
lowing cervical treatment, 33 (16.6%) compared to 42 (21.1%) 
in cryotherapy.
There was no difference in mean cervical HIV RNA levels 
between arms in the first (incident rate ratio [IRR], 0.95; 95% 
confidence interval [CI], 0.87–1.04; P  =  .297), second (IRR, 
0.98; 95% CI, 0.88–1.09; P = .727), and third weeks (IRR, 0.98; 
95% CI, 0.87–1.10; P  =  .701) after cervical treatment in the 
unadjusted analysis (Figure 2).
Adjusting for baseline cervical HIV RNA, ART exposure, and 
plasma viral load, the mean rate of change in cervical shedding 
from baseline was similar between treatments at week 1 (aIRR, 
1.04; 95% CI, 0.98–1.10; P =  .203). However, the risk of HIV 
cervical shedding in the LEEP arm was significantly increased 
compared to the cryotherapy arm at week 2 (aIRR, 1.07; 95% CI, 
1.00–1.15; P = .038) and remained significant at week 3 (aIRR, 
1.08; 95% CI, 1.00–1.16; P = .046). The magnitude of difference 
in mean cervical HIV RNA levels between the treatment arms 
in the adjusted analysis was consistently higher in the LEEP arm 
and ranged from 0.03 to 0.12 log10 copies during follow-up.
Cervical HIV Shedding Within the LEEP Arm
Women treated with LEEP showed a significant increase in 
mean cervical HIV RNA between week 1 and baseline from 
1.80 to 1.92 log10 copies (P = .009). Cervical HIV RNA levels 
further increased at week 2 to 2.03 log10 copies (P < .001) and 
week 3 to 2.04 log10 copies (P < .001). LEEP’s effect on cer-
vical HIV RNA levels remained statistically significant after 
adjusting for plasma HIV RNA levels in multivariate ana-
lysis. Among the subset of women on ART who were treated 
with LEEP, the mean cervical viral load increased from base-
line at weeks 2 and 3 (week 2 mean HIV RNA increased to 
1.88 log10 copies [P =  .002] and at week 3, 1.93 log10 copies 
[P = .002]). Among women off ART, cervical HIV RNA lev-
els increased from a baseline of 2.29 log10 copies  to 3.02 log10 
copies (P < 0.001) at week 1, 3.56 log10 copies (P < 0.001) at 
week 2, and 3.36 log10 copies (P < 0.001) at week 3 (Table 2).
Cervical HIV Shedding Within the Cryotherapy Arm
Mean cervical HIV RNA levels for women treated with cryo-
therapy were 2.02 log10 copies at baseline and did not signif-
icantly increase at week 1 (1.96 log10 copies; P  =  .566), week 
2 (2.04 log10 copies; P  =  .150), or week 3 (2.12 log10 copies; 
P = .122; Table 3). The lack of association persisted in analyses 
adjusting for plasma viral load. Among the subset of women 
on ART randomized to cryotherapy, cervical HIV RNA levels 
did not increase at weeks 1 (1.82 log10 copies; P = .627), 2 (1.86 
log10 copies; P = .877) 2, or 3 (1.86 log10 copies; P = .831) above 
baseline. Among women off ART, mean cervical HIV RNA 
was unchanged at week 1 (2.83 log10 copies; P = .812) following 
cryotherapy. However, at weeks 2 and 3, mean HIV RNA levels 
400 Randomized
200 Assigned Cryotherapy 200 Assigned LEEP
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Figure 1. Participant flow of randomization and follow-up in the trial. aThe cervical swab volume collected was <300 μL. bThe study participant did not attend a follow-up 
study visit at week 1, week 2, or week 3. cFollow-up study visits did not occur within ±3 days of 7, 14, or 21 days post-treatment. dThe expected number of women at weeks 
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significantly increased to 3.31 log10 copies (P = .011) and 3.80 
log10 copies (P = .002), respectively.
DISCUSSION
In this study we examined the impact of LEEP and cryotherapy on 
cervical HIV shedding. Women treated with LEEP had significantly 
higher mean cervical HIV RNA levels compared to those who were 
treated with cryotherapy for 3 weeks following treatment. Women 
treated with LEEP had higher cervical HIV RNA levels throughout 
the follow-up period compared to baseline, regardless of ART sta-
tus or plasma viral load. In contrast, cervical HIV RNA levels did 
not increase after treatment with cryotherapy or among women on 
ART. Among women treated with cryotherapy, only women off 
ART had higher HIV RNA levels during follow-up.
Table 2. Change in Mean Cervical Human Immunodeficiency Virus RNA (log10 copies/swab) Among Women Treated With Loop Electrosurgical Excision 
Procedure
Time Mean (copies/ swab)
Absolute Mean Change From 
Baseline (95% CI)a Unadjusted IRRb (95% CI) P Value Adjusted IRRb (95% CI) P Value
Overallc (n = 200)
Baseline 1.80 - - - -
Week 1 1.92 0.10 (0.02–0.18) 1.06 (1.01–1.10) .009 1.06 (1.01–1.11) .010
Week 2 2.03 0.25 (0.14–0.37) 1.14 (1.08–1.21) <.001 1.17 (1.10–1.24) <.001
Week 3 2.04 0.26 (0.14–0.38) 1.14 (1.08–1.21) <.001 1.17 (1.10–1.25) <.001
On ARTd (n = 183)
Baseline 1.76 - - - -
Week 1 1.81 0.05 (-0.02–0.12) 1.02 (0.98–1.06) .281 1.03 (0.98–1.07) .220
Week 2 1.88 0.16 (0.07–0.26) 1.09 (1.03–1.15) .002 1.11 (1.05–1.18) <.001
Week 3 1.93 0.18 (0.08–0.29) 1.10 (1.04–1.17) .002 1.13 (1.06–1.21) <.001
Off ARTd (n = 17)
Baseline 2.29 - - - -
Week 1 3.02 0.74 (0.27–1.20) 1.32 (1.16–1.52) .000 1.35 (1.13–1.61) .001
Week 2 3.56 1.22 (0.70–1.74) 1.51 (1.27–1.80) <.001 1.57 (1.32–1.87) <.001
Week 3 3.36 1.08 (0.54–1.62) 1.49 (1.26–1.77) <.001 1.51 (1.26–1.80) <.001
Abbreviations: ART, antiretroviral therapy; CI, confidence interval; IRR, incident rate ratio.
aAbsolute change and 95% CI of cervical log10 copies/swab human immunodeficiency virus (HIV) RNA in comparison to baseline.
bIRR and 95% CI in comparison to baseline.
cAdjusted for ART and detectable plasma HIV RNA.
dAdjusted for detectable plasma HIV RNA.
Table 3. Change in Mean Cervical Human Immunodeficiency Virus RNA (log10 copies/swab) Among Women Treated With Cryotherapy
Time Mean log10 Copies
Absolute Mean Change From Baseline 
(95% CI)a Unadjusted IRRb (95% CI) P Value Adjusted IRRb (95% CI) P Value
Overallc (n = 200)
Baseline 2.02 - - - -
Week 1 1.96 −0.02 (−0.11 to 0.06) 0.99 (0.95 to 1.03) .566 0.98 (0.94–1.03) .390
Week 2 2.04 0.07 (−0.02 to 0.16) 1.04 (0.99 to 1.09) .150 1.04 (0.99–1.10) .102
Week 3 2.12 0.05 (−0.05 to 0.14) 1.04 (0.99 to 1.10) .122 1.05 (0.99–1.11) .104
On ARTd (n = 172)
Baseline 1.88 - - - -
Week 1 1.82 −0.02 (−0.11 to 0.06) 0.99 (0.95 to 1.03) .627 0.98 (0.93–1.03) .386
Week 2 1.86 0.03 (−0.06 to 0.12) 1.00 (0.96 to 1.05) .877 1.01 (0.96–1.07) .658
Week 3 1.86 −0.01 (−0.11 to 0.08) 0.99 (0.94 to 1.05) .831 1.00 (0.94–1.05) .899
Off ARTd (n = 28)
Baseline 2.88 - - - -
Week 1 2.83 −0.04 (−0.33 to 0.26) 0.99 (0.89 to 1.09) .812 0.99 (0.88–1.11) .864
Week 2 3.31 0.45 (0.03 to 0.86) 1.18 (1.04 to 1.35) .011 1.17 (1.02–1.34) .024
Week 3 3.80 0.68 (0.18 to 1.17) 1.25 (1.08 to 1.44) .002 1.25 (1.07–1.45) .004
Abbreviations: ART, antiretroviral therapy; CI, confidence interval; IRR, incident rate ratio.
aAbsolute change and 95% CI of cervical log10 copies/swab human immunodeficiency virus (HIV) RNA in comparison to baseline.
bIRR and 95% CI of cervical log10 copies/swab HIV RNA in comparison to baseline.
cAdjusted for ART and detectable plasma HIV RNA.
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The results of our study are consistent with a recent study 
that demonstrated that LEEP treatment resulted in a signifi-
cant short-term increase in HIV shedding at 2 weeks follow-
ing treatment, which returned to baseline by 4 weeks [22]. 
Immune activation in the genital tract recruits CD4+ T cells 
to the area of tissue damage, increasing HIV target cells [27]. 
Proinflammatory cytokines predict HIV shedding [18, 28], 
and higher levels of cervical HIV RNA and proinflammatory 
cytokines have been measured following CIN treatment [21]. 
As an excisional procedure, LEEP removes both the lesion and 
healthy cervical tissue around the lesion [22]. The subsequent 
ulceration that results from LEEP treatment covers a greater 
surface area and may thereby promote a greater inflamma-
tory response than cryotherapy [11]. Depending on the size of 
the loop electrode used, tissue should be excised to a depth of 
6–7 mm, but it is not uncommon for the depth of tissue removal 
to exceed 10 mm [4, 29]. By removing cells of both the ecto- and 
endocervix, LEEP may contribute to HIV shedding from the 
upper genital tract in addition to the lower tract [30]. In con-
trast, cryotherapy causes necrosis and damage to ectocervical 
cells by freezing tissue up to 5–7 mm deep [31]. Typical CIN2/3 
lesions are <5 mm in depth from the surface [32]. Compared to 
LEEP, the inflammation following cryotherapy treatment may 
be more localized and therefore cause less HIV shedding.
The transmission risk of female-to-male HIV transmission 
has been shown to be 1.56-fold higher for every 1-log10 increase 
in cervical HIV RNA after adjusting for plasma HIV RNA [14]. 
In our study, the magnitude of change in cervical HIV RNA from 
baseline was <0.20 log10 among women on ART in both LEEP 
and cryotherapy cohorts. However, localized inflammation 
is significantly associated with increased cervical HIV shed-
ding [33], and women on ART with undetectable plasma HIV 
RNA have still been found to shed HIV from the cervix [34, 
35]. Women not on ART experienced a mean change of >1-log 
change following LEEP and 0.68 log10 following cryotherapy. 
ART appears to modulate changes in cervical HIV levels, and 
thus the risk of sexual HIV transmission may not pose a substan-
tial risk for women on ART. However, there may be increased 
infectivity among women who are not on ART at the time of 
cervical treatment, particularly among those receiving LEEP.
Our study has several limitations. First, we reported an im-
balance between arms in cervical HIV RNA at baseline, and 
we addressed this by adjusting for baseline cervical viral load. 
Second, the study was limited by the number of women not on 
ART, which decreased the precision of the study to evaluate 
the effect of treatment and the role of ART. While these data 
are informative for clinical decision-making, further research 
on the role of ART in mitigating post-treatment cervical HIV 
shedding is warranted to more effectively assess the risk of HIV 
transmission. We only measured cervical HIV shedding for 3 
weeks after treatment and did not determine when cervical viral 
load returned to baseline. However, prior studies have shown 
that cervical HIV RNA levels return to baseline after 4 weeks 
[22, 23], suggesting that uncomplicated treatment results only 
in short-term changes to the cervix that were likely captured 
within the course of the study.
As access to ART continues to expand globally and HIV-
infected women are living healthier and more productive lives, 
screening and treatment for cervical cancer may be a critical 
component in further extending their quality of life. The results 
Figure 2. Weekly treatment level mean cervical and plasma human immunodeficiency virus RNA over 3 weeks of follow-up. Abbreviations: HIV, human immunodeficiency 
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of our study support the current guidelines that HIV-infected 
women avoid sexual intercourse for 1 month after treatment to 
allow the wound to heal or to practice risk-reduction strategies to 
minimize risk of HIV transmission. Our data indicate that there 
is an increase in cervical HIV shedding that differs by treatment 
procedure and ART status and that HIV-infected women should 
be counseled on the risk of HIV sexual transmission. Our results 
suggest that cryotherapy used in resource-limited settings likely 
does not contribute to HIV transmission during the immediate 
post-procedure period and is optimally performed when women 
are on ART to minimize cervical shedding. LEEP treatment may 
contribute to a time-limited increase in HIV infectivity among 
women not on ART, and these changes likely occur within the 
1-month interval following treatment.
Notes
Acknowledgments. We thank the research personnel, clinic and lab-
oratory staff, and data management teams in Nairobi, Kenya, Seattle, 
Washington, and Lyon, France, for their work. We appreciate the Coptic 
Hope Center for Infectious Diseases for their cooperation. Most of all, we 
thank the women for participation in the study.
Funding. This research has been supported by the President’s 
Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease 
Control and Prevention (CDC) under the terms of cooperative agreements 
GH002036 and GH002001.
Potential conflicts of interest. All authors: No reported conflicts of 
interest. All authors have submitted the ICMJE Form for Disclosure of 
Potential Conflicts of Interest. Conflicts that the editors consider relevant to 
the content of the manuscript have been disclosed.
References
1. De Vuyst H, Alemany L, Lacey C, et  al. The burden of human papillomavirus 
infections and related diseases in sub-Saharan Africa. Vaccine 2013; 31(Suppl 
5):F32–46.
2. Harris TG, Burk RD, Palefsky JM, et al. Incidence of cervical squamous intraepi-
thelial lesions associated with HIV serostatus, CD4 cell counts, and human papil-
lomavirus test results. JAMA 2005; 293:1471–6.
3. Massad LS, Einstein MH, Huh WK, et al. 2012 updated consensus guidelines for 
the management of cervical cancer screening test and cancer precursors. Am Soc 
Colposc Cerv Pathol 2013; 17:S1–27.
4. Jordan J, Martin-Hirsch P, Arbyn M, et al. European guidelines for clinical man-
agement of abnormal cervical cytology, part 2. Cytopathology 2009; 20:5–16.
5. Denny L, Kuhn L, De Souza M, Pollack AE, Dupree W, Wright TC Jr. Screen-
and-treat approaches for cervical cancer prevention in low-resource settings: a 
randomized controlled trial. JAMA 2005; 294:2173–81.
6. Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD, et al; Alliance for Cervical Cancer 
Prevention Cost Working Group. Cost-effectiveness of cervical-cancer screening 
in five developing countries. N Engl J Med 2005; 353:2158–68.
7. Sankaranarayanan R, Anorlu R, Sangwa-Lugoma G, Denny LA. Infrastructure 
requirements for human papillomavirus vaccination and cervical cancer screen-
ing in sub-Saharan Africa. Vaccine 2013; 31(Suppl 5):F47–52.
8. Sankaranarayanan R, Nene BM, Dinshaw KA, et al; Osmanabad District Cervical 
Screening Study Group. A cluster randomized controlled trial of visual, cytology 
and human papillomavirus screening for cancer of the cervix in rural India. Int J 
Cancer 2005; 116:617–23.
9. Lince-Deroche N, Phiri J, Michelow P, Smith JS, Firnhaber C. Costs and cost 
effectiveness of three approaches for cervical cancer screening among HIV-
positive women in Johannesburg, South Africa. PLoS One 2015; 10:e0141969.
10. Chamot E, Kristensen S, Stringer JS, Mwanahamuntu MH. Are treatments for 
cervical precancerous lesions in less-developed countries safe enough to promote 
scaling-up of cervical screening programs? A systematic review. BMC Womens 
Health 2010; 10:11.
11. Wright TC Jr, Subbarao S, Ellerbrock TV, et al. Human immunodeficiency virus 
1 expression in the female genital tract in association with cervical inflammation 
and ulceration. Am J Obstet Gynecol 2001; 184:279–85.
12. Wang CC, McClelland RS, Reilly M, et al. The effect of treatment of vaginal infec-
tions on shedding of human immunodeficiency virus type 1. J Infect Dis 2001; 
183:1017–22.
13. Chirenje ZM, Rusakaniko S, Akino V, Mlingo M. A randomised clinical trial of 
loop electrosurgical excision procedure (LEEP) versus cryotherapy in the treat-
ment of cervical intraepithelial neoplasia. J Obstet Gynaecol 2001; 21:617–21.
14. Baeten JM, Kahle E, Lingappa JR, et al. Genital HIV-1 RNA quantity predicts risk 
of heterosexual HIV-1 transmission. Sci Transl Med 2011; 3:1–15.
15. Launay O, Tod M, Tschöpe I, et  al; ANRS EP24 GYNODYN Study Group. 
Residual HIV-1 RNA and HIV-1 DNA production in the genital tract reservoir 
of women treated with HAART: the prospective ANRS EP24 GYNODYN study. 
Antivir Ther 2011; 16:843–52.
16. Mhatre M, McAndrew T, Carpenter C, Burk RD, Einstein MH, Herold BC. 
Cervical intraepithelial neoplasia is associated with genital tract mucosal inflam-
mation. Sex Transm Dis 2012; 39:591–7.
17. Johnson LF, Lewis DA. The effect of genital tract infections on HIV-1 shedding in the 
genital tract: a systematic review and meta-analysis. Sex Transm Dis 2008; 35:946–59.
18. Mitchell C, Hitti J, Paul K, et al. Cervicovaginal shedding of HIV type 1 is related 
to genital tract inflammation independent of changes in vaginal microbiota. 
AIDS Res Hum Retroviruses 2011; 27:35–9.
19. Gitau RW, Graham SM, Masese LN, et al. Effect of acquisition and treatment of 
cervical infections on HIV-1 shedding in women on antiretroviral therapy. AIDS 
2010; 24:2733–7.
20. Fiore JR, Suligoi B, Saracino A, et al. Correlates of HIV-1 shedding in cervicovag-
inal secretions and effects of antiretroviral therapies. AIDS 2003; 17:2169–76.
21. Lawn SD, Subbarao S, Wright TC Jr, et al. Correlation between human immuno-
deficiency virus type 1 RNA levels in the female genital tract and immune activa-
tion associated with ulceration of the cervix. J Infect Dis 2000; 181:1950–6.
22. Huchko MJ, Woo VG, Liegler T, et  al. Impact of loop electrosurgical excision 
procedure for cervical intraepithelial neoplasia on HIV-1 genital shedding: a pro-
spective cohort study. BJOG 2013; 120:1233–9.
23. Chung MH, McKenzie KP, Richardson BA, et al. Cervical HIV-1 RNA shedding 
after cryotherapy among HIV-positive women with cervical intraepithelial neo-
plasia stage 2 or 3. AIDS 2011; 25:1915–9.
24. Forhan SE, Godfrey CC, Watts DH, Langley CL. A systematic review of the effects 
of visual inspection with acetic acid, cryotherapy, and loop electrosurgical exci-
sion procedures for cervical dysplasia in HIV-infected women in low- and mid-
dle-income countries. J Acquir Immune Defic Syndr 2015; 68(Suppl 3):S350–6.
25. Greene SA, Nyongesa-Malava E, Richardson BA, et al. Randomized trial of LEEP 
vs cryotherapy to treat CIN 2/3 in HIV-infected women. In: Conference on 
Retroviruses and Opportunistic Infections. Seattle, Washington, 2017.
26. Chung MH, Drake AL, Richardson BA, et  al. Impact of prior HAART use on 
clinical outcomes in a large Kenyan HIV treatment program. Curr HIV Res 2009; 
7:441–6.
27. Jaspan HB, Liebenberg L, Hanekom W, et al. Immune activation in the female 
genital tract during HIV infection predicts mucosal CD4 depletion and HIV 
shedding. J Infect Dis 2011; 204:1550–6.
28. Nkwanyana NN, Gumbi PP, Roberts L, et  al. Impact of human immunodefi-
ciency virus 1 infection and inflammation on the composition and yield of cer-
vical mononuclear cells in the female genital tract. Immunology 2009; 128(1 
Suppl):e746–57.
29. Noehr B, Jensen A, Frederiksen K, Tabor A, Kjaer SK. Depth of cervical cone 
removed by loop electrosurgical excision procedure and subsequent risk of spon-
taneous preterm delivery. Obstet Gynecol 2009; 114:1232–8.
30. Coleman JS, Hitti J, Bukusi EA, et al. Infectious correlates of HIV-1 shedding in 
the female upper and lower genital tracts. AIDS 2007; 21:755–9.
31. Khan MJ, Smith-McCune KK. Treatment of cervical precancers: back to basics. 
Obstet Gynecol 2014; 123:1339–43.
32. Abdul-Karim FW, Fu YS, Reagan JW, Wentz WB. Morphometric study of intraep-
ithelial neoplasia of the uterine cervix. Obstet Gynecol 1982; 60:210–4.
33. Blish CA, McClelland RS, Richardson BA, et al. Genital inflammation predicts 
HIV-1 shedding independent of plasma viral load and systemic inflammation. J 
Acquir Immune Defic Syndr 2012; 61:436–40.
34. Neely MN, Benning L, Xu J, et  al. Cervical shedding of HIV-1 RNA among 
women with low levels of viremia while receiving highly active antiretroviral 
therapy. J Acquir Immune Defic Syndr 2007; 44:38–42.
35. Cu-Uvin S, DeLong AK, Venkatesh KK, et al. Genital tract HIV-1 RNA shedding 








niversity user on 08 June 2021
